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lar growth and migration factor and as a proinflamma-Factor XIIIA (Cross)Links AT1 tory cytokine that influences the infiltration and activitiesReceptors to Atherosclerosis of macrophages and T lymphocytes.
Two distinct subtypes of angiotensin II receptors, type
1 (AT1) and type 2 (AT2), have been identified, and both
have been shown to belong to the G protein-coupledAngiotensin II, a small peptide hormone that plays key
receptor (GPCR) superfamily. Increasing evidence sug-roles in the regulation of blood pressure, also contrib-
gests that a dimer is the minimal functional structure,utes to inflammatory processes that promote the de-
but considerable variation exists between reports onvelopment of atherosclerosis. In this issue of Cell,
the effects of agonists on quaternary structure. The AT1AbdAlla et al. (2004) provide evidence that pathogenic
receptor forms heterodimers with various other recep-actions of angiotensin II involve covalent crosslinking
tors such as the bradykinin B2 receptor, the AT2 receptor,of angiotensin AT1 receptors by factor XIIIA transglu-
the 2-adrenergic receptor, and the dopamine D1 recep-taminase, resulting in stable receptor dimers with en-
tor. Heterodimerization of the AT1 receptor with the B2hanced signaling properties.
receptor specifically enhances angiotensin II-stimulated
signaling in platelets and vessels of patients with pre-Atherosclerosis is a complex, chronic disease state that
eclampsia, a disorder of pregnancy that is characterizedusually arises from the convergence of several patho-
by a rapidly progressive rise in blood pressure and thegenic processes, including hypertension, hyperlidemia,
presence of protein in the urine (AbdAlla et al., 2000,obesity, and insulin resistance. The earliest visible mani-
2001). AT1/bradykinin B2 receptor heterodimerizationfestation of atherosclerosis is the fatty streak, which
does not seem to contribute to the enhanced angioten-develops when monocyte-derived macrophages accu-
sin II responsiveness of monocytes, however, becausemulate beneath the endothelial cell lining of large arter-
monocytes do not express significant amounts of B2ies and become massively engorged with cholesterol.
receptors. The AT1 receptor is also reported to formWhile not clinically significant in themselves, fatty
homodimers, raising the possibility that they are thestreaks can evolve into large, complex lesions that ex-
relevant signaling species in this cell type.hibit characteristics of a chronic inflammatory process.
While many studies have intimated the existence ofAs lesions progress in size, they often develop a necrotic
homo- and heterodimeric GPCR pairings, key questionscore of lipid and cellular debris that is surrounded by a
remain regarding their prevalence and physiological rel-fibrous cap (Glass and Witztum, 2001). The nature and
evance. What unfolds in this issue of Cell is evidenceextent of the inflammatory response within an athero-
that angiotensin II induces covalent dimerization of AT1sclerotic lesion contribute to its susceptibility to rupture,
receptors mediated by factor XIIIA transglutaminase,which can in turn initiate local thrombosis and the ensu-
revealing a novel mechanism regulating GPCR signalinging complications of acute myocardial infarction and
that is of biological and clinical significance (AbdAlla etstroke.
al., 2004). Crosslinked AT1 receptor dimers exhibitedThe renin-angiotensin system plays an important ho-
enhanced signaling and desensitization in vitro and
meostatic role in regulating blood volume, arterial pres-
in vivo. Intriguingly, levels of factor XIIIA activity and AT1sure, and cardiac and vascular function. Renin acts upon
receptor dimers were significantly higher in monocytes
circulating angiotensinogen to form the decapeptide,
derived from hypertensive patients than in monocytes
angiotensin I, which is further processed by angiotensin- derived from normal subjects and correlated with an
converting enzyme (ACE), to form the octapeptide hor- enhanced angiotensin II-dependent monocyte adhesion
mone angiotensin II. Among its many activities, angio- to endothelial cells. Furthermore, factor XIIIA activity
tensin II is an extremely potent pressor agent, acutely and the levels of AT1 dimers in hypertensive patients
raising blood pressure by acting upon type 2 angiotensin could be reduced or normalized by chronic treatment
AII receptors in arterial resistance vessels. The activity with an inhibitor of ACE. Monocytes derived from hyper-
of the renin-angiotensin system is tightly regulated by cholesterolemic mice also demonstrated increased lev-
multiple hormonal and hemodynamic inputs to maintain els of AT1 dimers that could be reduced by treatment
blood pressure, blood volume, and cardiac function un- with an ACE inhibitor or by expression of an inhibitor of
der different environmental and physiological states. factor XIIIA. Expression of the factor XIIIA inhibitor also
Several aspects of this system, including the capacity reduced monocyte entry into the artery wall and inhib-
for angiotensin II synthesis and binding, are increased ited development of atherosclerosis in hypercholester-
in the setting of hypertension and atherosclerosis in olemic mice. These findings point to a significant contri-
humans (Daugherty and Cassis, 2004). Exogenous ad- bution of covalent dimerization of AT1 receptors in
ministration of angiotensin II accelerates vascular lesion pathogenic events that drive lesion formation. Key patho-
formation in animal models, while inhibition of angioten- physiological questions that remain to be resolved in-
sin II synthesis or activity has been shown to significantly clude why the monocytic angiotensin II-AT1 system is
reduce atherosclerosis and cardiovascular mortality in activated in the settings of hypertension and hypercho-
both human and animal studies. A significant compo- lesterolemia and how treatment with ACE inhibitors re-
nent of the cardiovascular protection observed in these duces factor XIIIA activity.
studies appears to be independent of blood pressure, The finding that covalent crosslinking of AT1 receptor
suggesting important and direct roles for the vascular homodimers enhances their signaling activities raises a
renin-angiotensin system within the artery wall itself. number of mechanistic questions for future exploration.
Angiotensin II has numerous effects on cellular compo- One possible structural explanation for enhanced acti-
vation and signaling by AT1 dimers is based on recentnents of atherosclerotic lesions, functioning as a vascu-
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140–156.suggest the existence of constitutively active AT1 recep-
tors, which appear to form stable dimers independent
of covalent crosslinking (Hansen et al., 2004). It remains
to be determined how the covalent AT1 dimers differ from
the preformed AT1 dimers that are not covalently linked. Chronic Myeloid Leukemia:
It will also be of interest to determine whether analo-
Proving Ground for Cancergous mechanisms apply to other GPCR homo- or het-
erodimeric pairings. A factor XIIIA-dependent crosslink- Stem Cells
ing mechanism may be unique for AT1 dimers, as AT1/
B2 receptor heterodimers are not sensitive to inhibition
of factor XIIIA. However, genome sequencing efforts
have revealed the existence of 700–800 mammalian A central question in cancer biology is whether malig-
nancy arises in self-renewing tissue stem cells thatGPCRs, about 250 of which are identified as receptors
for known ligands, with the rest still classified as orphan suffer oncogene activation or in differentiated cells
that acquire properties of unremitting self-renewal?receptors (oGPCRs). The identification of transglutami-
nase-dependent crosslinking as a regulatory mecha- In two papers, Weissman and colleagues document
both mechanisms: chronic leukemia arising by muta-nism for other GPCRs could be of potential importance
in drug discovery efforts. The present studies also raise tion affecting the hematopoietic stem cell (HSC) and
acute leukemia evolving from committed granulocyte-the possibility that, in disorders, such as Huntington’s
disease and Alzheimer’s disease, with enhanced trans- macrophage progenitors that have acquired the self-
renewal machinery of HSCs.glutaminase expression and activity (Lesort et al., 2000),
covalent receptor dimer stabilization of specific GPCRs
apart from AT1 could be of pathological relevance. Po- Human chronic myeloid leukemia (CML) is a myeloprolif-
tential roles of other members of the transglutaminase erative disorder (MPD) caused by the Philadelphia chro-
family are unclear. For example, in contrast to factor mosome translocation, a t(9;22) that generates the BCR/
XIIIA, transglutaminase 2 (tissue transglutaminase) was ABL fusion oncoprotein. Several features suggest that
not effective in stabilizing angiotensin II-induced AT1 CML has its origins in the HSC. The Philadelphia chro-
dimers (AbdAlla et al., 2004; Lorand and Graham, 2003). mosome can be detected in both myeloid and lymphoid
The dynamic interplay between constitutive GPCR cells, and evolution of the disease into an acute leukemia
clustering, ligand-induced receptor rearrangements, can affect either the myeloid or lymphoid lineages. Rein-
and specific biological or pathological outcomes will be forcing its stem cell origins, traditional cytotoxic chemo-
a significant avenue of future investigation (Franco et therapy fails to induce a cytogenetic remission in CML.
al., 2003). The discovery that factor XIIIA-dependent In murine models, when retroviruses specifying BCR/
crosslinking of AT1 receptors potentiates angiotensin II ABL infect the hematopoietic stem cell (as evidenced
signaling raises the possibility that inhibition of covalent by common retroviral integration sites in myeloid and
dimer formation might provide the basis for novel thera- lymphoid lineages), the resulting disease closely resem-
peutic interventions. bles human CML (Daley et al., 1990; Li et al., 1999). In
contrast, when retroviruses infect committed progeni-
tors, acute leukemias arise with a single proviral integra-Sumito Ogawa and Christopher K. Glass
tion site, implying the selection of a leukemic subclone
Department of Cellular and Molecular Medicine
carrying additional genetic changes. Leukemia thus pro-
University of California, San Diego
vides a proving ground for studies of the target cell of
9500 Gilman Drive
origin in malignancy.
La Jolla, California 92093
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